aTyr Pharma (NASDAQ:LIFE) was downgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Saturday, November 18th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $4.81.

Shares of aTyr Pharma (NASDAQ:LIFE) opened at $3.50 on Wednesday. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a 52-week low of $2.30 and a 52-week high of $6.50. The company has a market capitalization of $101.18, a P/E ratio of -1.72 and a beta of 3.60.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. sell-side analysts expect that aTyr Pharma will post -1.93 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of LIFE. Artal Group S.A. lifted its position in shares of aTyr Pharma by 100.0% during the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares during the period. Renaissance Technologies LLC lifted its position in shares of aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after buying an additional 164,500 shares during the period. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma during the 3rd quarter worth approximately $455,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares during the period. Institutional investors and hedge funds own 58.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “aTyr Pharma (LIFE) Cut to Underweight at JPMorgan Chase & Co.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/02/14/atyr-pharma-life-cut-to-underweight-at-jpmorgan-chase-co.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

The Fly

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.